文章：

西班牙慢性淋巴细胞白血病患者的临床特征和管理的真实世界证据：自然语言处理的应用——SRealCLL研究

Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study

原文发布日期：10 August 2023

DOI: 10.3390/cancers15164047

类型: Article

开放获取: 是

英文摘要：

The SRealCLL study aimed to obtain real-world evidence on the clinical characteristics and treatment patterns of patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP). Electronic health records (EHRs) from seven Spanish hospitals (January 2016–December 2018) were analyzed using EHRead®technology, based on NLP and machine learning. A total of 534 CLL patients were assessed. No treatment was detected in 270 (50.6%) patients (watch-and-wait, W&W). First-line (1L) treatment was identified in 230 (43.1%) patients and relapsed/refractory (2L) treatment was identified in 58 (10.9%). The median age ranged from 71 to 75 years, with a uniform male predominance (54.8–63.8%). The main comorbidities included hypertension (W&W: 35.6%; 1L: 38.3%; 2L: 39.7%), diabetes mellitus (W&W: 24.4%; 1L: 24.3%; 2L: 31%), cardiac arrhythmia (W&W: 16.7%; 1L: 17.8%; 2L: 17.2%), heart failure (W&W 16.3%, 1L 17.4%, 2L 17.2%), and dyslipidemia (W&W: 13.7%; 1L: 18.7%; 2L: 19.0%). The most common antineoplastic treatment was ibrutinib in 1L (64.8%) and 2L (62.1%), followed by bendamustine + rituximab (12.6%), obinutuzumab + chlorambucil (5.2%), rituximab + chlorambucil (4.8%), and idelalisib + rituximab (3.9%) in 1L and venetoclax (15.5%), idelalisib + rituximab (6.9%), bendamustine + rituximab (3.5%), and venetoclax + rituximab (3.5%) in 2L. This study expands the information available on patients with CLL in Spain, describing the diversity in patient characteristics and therapeutic approaches in clinical practice.

摘要翻译： 

SRealCLL研究旨在通过自然语言处理技术获取慢性淋巴细胞白血病患者的临床特征与治疗模式的真实世界证据。研究采用基于自然语言处理和机器学习的EHRead®技术，分析了七所西班牙医院的电子健康记录（2016年1月至2018年12月）。共评估534例CLL患者，其中270例（50.6%）未接受治疗（观察等待组），230例（43.1%）接受一线治疗，58例（10.9%）接受复发/难治性二线治疗。患者中位年龄范围71-75岁，男性占主导（54.8%-63.8%）。主要合并症包括高血压（观察等待组35.6%；一线组38.3%；二线组39.7%）、糖尿病（24.4%；24.3%；31%）、心律失常（16.7%；17.8%；17.2%）、心力衰竭（16.3%；17.4%；17.2%）及血脂异常（13.7%；18.7%；19.0%）。最常见的抗肿瘤治疗方案为一线和二线均以伊布替尼为主（一线64.8%，二线62.1%），一线治疗后续方案包括苯达莫司汀+利妥昔单抗（12.6%）、奥妥珠单抗+苯丁酸氮芥（5.2%）、利妥昔单抗+苯丁酸氮芥（4.8%）及艾德拉尼+利妥昔单抗（3.9%）；二线治疗后续方案包括维奈克拉（15.5%）、艾德拉尼+利妥昔单抗（6.9%）、苯达莫司汀+利妥昔单抗（3.5%）及维奈克拉+利妥昔单抗（3.5%）。本研究拓展了西班牙CLL患者的临床信息，揭示了临床实践中患者特征与治疗策略的多样性。

原文链接：

Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study